PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease, announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
November 29, 2023
· 4 min read